Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer

Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer

Conditions: Differentiated Thyroid Cancer; Pediatric Cancer; Cancer; Cancer, Thyroid
Interventions: Drug: Larotrectinib monotherapy; Radiation: 131I therapy
Sponsors: Children’s Hospital of Philadelphia; Bayer
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

February 17, 2024Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments